DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Whether Hoosier Healthwise / HIP covers Wegovy, Zepbound, Ozempic, or Mounjaro for weight loss and type 2 diabetes, prior authorization rules, and routes when coverage is denied.
HIP 2.0 covers weight-loss GLP-1 with documented prior efforts. Submit prior authorization through your prescriber, not directly. Approval decisions typically take 3-10 business days; expedited reviews for urgent cases process within 72 hours. Denials are appealable; first-round appeals succeed roughly 30-40% of the time when supporting documentation is thorough.
If Hoosier Healthwise / HIP denies coverage, the practical routes are: (1) manufacturer cash-pay channels like NovoCare Direct (Wegovy at $499/month) and LillyDirect (Zepbound at $549/month), (2) compounded semaglutide or tirzepatide via telehealth (lower price but not FDA-approved; supply tightening after the May 2026 shortage resolution), or (3) charity care through patient assistance programs offered by Novo Nordisk and Eli Lilly for low-income patients.
Standard parity; in-state collaboration preferred. Major telehealth providers operating in Indiana include ro body, form health.
Coverage variable by managed-care plan.
Editorial summary, not legal or medical advice. State Medicaid policies change frequently. Confirm current status with Hoosier Healthwise / HIP member services or your prescriber.